All Stories

  1. In VitroActivity of Gepotidacin, a Novel Triazaacenaphthylene Bacterial Topoisomerase Inhibitor, against a Broad Spectrum of Bacterial Pathogens

    Article • Antimicrobial Agents and Chemotherapy, January 2016, ASM Journals

    Mr Douglas J Biedenbach

  2. In VitroActivity of AZD0914, a Novel Bacterial DNA Gyrase/Topoisomerase IV Inhibitor, against Clinically Relevant Gram-Positive and Fastidious Gram-Negative Pathogens

    Article • Antimicrobial Agents and Chemotherapy, July 2015, ASM Journals

    Mr Douglas J Biedenbach

  3. In VitroActivity of Aztreonam-Avibactam against a Global Collection of Gram-Negative Pathogens from 2012 and 2013

    Article • Antimicrobial Agents and Chemotherapy, May 2015, ASM Journals

    Mr Douglas J Biedenbach

  4. In vitro susceptibility of Gram-negative isolates from patients with urinary tract infections in Vietnam: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART)

    Article • Journal of Global Antimicrobial Resistance, December 2014, Elsevier

    Mr Douglas J Biedenbach

  5. Dissemination of NDM Metallo-β-Lactamase Genes among Clinical Isolates of Enterobacteriaceae Collected during the SMART Global Surveillance Study from 2008 to 2012

    Article • Antimicrobial Agents and Chemotherapy, November 2014, ASM Journals

    Mr Douglas J Biedenbach

  6. In vitro activity of tigecycline and comparators against carbapenem-resistant Enterobacteriaceae in Africa–Middle East countries: TEST 2007–2012

    Article • Journal of Global Antimicrobial Resistance, September 2014, Elsevier

    Mr Douglas J Biedenbach

  7. Antimicrobial susceptibility and extended-spectrum beta-lactamase rates in aerobic gram-negative bacteria causing intra-abdominal infections in Vietnam: report from the Study for Monitoring Antimicrobial Resistance Trends (SMART 2009–2011)

    Article • Diagnostic Microbiology and Infectious Disease, August 2014, Elsevier

    Mr Douglas J Biedenbach

  8. Susceptibility of Staphylococcus aureus to Topical Agents in the United States: A Sentinel Study

    Article • Clinical Therapeutics, June 2014, Elsevier

    Mr Douglas J Biedenbach

  9. In vitro activity of tigecycline against isolates collected from complicated skin and skin structure infections and intra-abdominal infections in Africa and Middle East countries: TEST 2007–2012

    Article • Diagnostic Microbiology and Infectious Disease, May 2014, Elsevier

    Mr Douglas J Biedenbach

  10. Epidemiology and antimicrobial susceptibility of Gram-negative aerobic bacteria causing intra-abdominal infections during 2010–2011

    Article • Journal of Chemotherapy, February 2014, Taylor & Francis

    Mr Douglas J Biedenbach

  11. Evaluation of the Clinical and Laboratory Standards Institute phenotypic confirmatory test to detect the presence of extended-spectrum  -lactamases from 4005 Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae and Proteus mirabilis isolates

    Article • Journal of Medical Microbiology, January 2014, Society for General Microbiology

    Mr Douglas J Biedenbach

  12. Susceptibility of gram-negative aerobic bacilli from intra-abdominal pathogens to antimicrobial agents collected in the United States during 2011

    Article • Journal of Infection, January 2014, Elsevier

    Mr Douglas J Biedenbach

  13. A Review of Ten Years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011

    Article • Pharmaceuticals, November 2013, MDPI AG

    Mr Douglas J Biedenbach

  14. Potency and Spectrum of Activity of AN3365, a Novel Boron-Containing Protein Synthesis Inhibitor, Tested against Clinical Isolates of Enterobacteriaceae and Nonfermentative Gram-Negative Bacilli

    Article • Antimicrobial Agents and Chemotherapy, March 2013, ASM Journals

    Mr Douglas J Biedenbach

  15. Monitoring the global in vitro activity of ertapenem against Escherichia coli from intra-abdominal infections: SMART 2002–2010

    Article • International Journal of Antimicrobial Agents, March 2013, Elsevier

    Mr Douglas J Biedenbach

  16. Activity of JNJ-Q2, a novel fluoroquinolone, tested against Neisseria gonorrhoeae, including ciprofloxacin-resistant strains

    Article • Diagnostic Microbiology and Infectious Disease, October 2012, Elsevier

    Mr Douglas J Biedenbach

  17. Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia

    Article • International Journal of Antimicrobial Agents, April 2012, Elsevier

    Mr Douglas J Biedenbach

  18. Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs)

    Article • Journal of Antimicrobial Chemotherapy, January 2012, Oxford University Press (OUP)

    Mr Douglas J Biedenbach

  19. Antimicrobial Activity of the Investigational Pleuromutilin Compound BC-3781 Tested against Gram-Positive Organisms Commonly Associated with Acute Bacterial Skin and Skin Structure Infections

    Article • Antimicrobial Agents and Chemotherapy, January 2012, ASM Journals

    Mr Douglas J Biedenbach

  20. Surveillance of JNJ-Q2 activity tested against Staphylococcus aureus and beta-hemolytic streptococci as a component of the 2010 sentry antimicrobial surveillance program

    Article • Diagnostic Microbiology and Infectious Disease, December 2011, Elsevier

    Mr Douglas J Biedenbach

  21. JNJ-Q2, a New Fluoroquinolone with PotentIn VitroActivity against Staphylococcus aureus, Including Methicillin- and Fluoroquinolone-Resistant Strains

    Article • Antimicrobial Agents and Chemotherapy, May 2011, ASM Journals

    Mr Douglas J Biedenbach

  22. Antimicrobial characterisation of solithromycin (CEM-101), a novel fluoroketolide: activity against staphylococci and enterococci

    Article • International Journal of Antimicrobial Agents, January 2011, Elsevier

    Mr Douglas J Biedenbach, Dr. Mariana Castanheira

  23. In VitroActivity and Single-Step Mutational Analysis of Rifamycin SV Tested against Enteropathogens Associated with Traveler's Diarrhea andClostridium difficile

    Article • Antimicrobial Agents and Chemotherapy, December 2010, ASM Journals

    Mr Douglas J Biedenbach

  24. Stability of linezolid activity in an era of mobile oxazolidinone resistance determinants: results from the 2009 Zyvox® Annual Appraisal of Potency and Spectrum program

    Article • Diagnostic Microbiology and Infectious Disease, December 2010, Elsevier

    Mr Douglas J Biedenbach

  25. Update on Fusidic Acid (CEM-102) Tested against Neisseria gonorrhoeae and Chlamydia trachomatis

    Article • Antimicrobial Agents and Chemotherapy, July 2010, ASM Journals

    Mr Douglas J Biedenbach

  26. Determination of CEM-101 Activity Tested against Clinical Isolates of Neisseria meningitidis from a Worldwide Collection

    Article • Antimicrobial Agents and Chemotherapy, July 2010, ASM Journals

    Mr Douglas J Biedenbach

  27. Antimicrobial characterisation of CEM-101 activity against respiratory tract pathogens, including multidrug-resistant pneumococcal serogroup 19A isolates

    Article • International Journal of Antimicrobial Agents, June 2010, Elsevier

    Mr Douglas J Biedenbach, Dr. Mariana Castanheira

  28. In Vitro Activity of Fidaxomicin (OPT-80) Tested against Contemporary Clinical Isolates of Staphylococcus spp. and Enterococcus spp.

    Article • Antimicrobial Agents and Chemotherapy, March 2010, ASM Journals

    Mr Douglas J Biedenbach

  29. Spectrum of activity, mutation rates, synergistic interactions, and the effects of pH and serum proteins for fusidic acid (CEM-102)

    Article • Diagnostic Microbiology and Infectious Disease, March 2010, Elsevier

    Mr Douglas J Biedenbach

  30. Five-year trend of antimicrobial susceptibility rates and daptomycin activity among Staphylococcus aureus isolates collected in Latin American medical eenters (2005-2009)

    Article • International Journal of Infectious Diseases, March 2010, Elsevier

    Mr Douglas J Biedenbach

  31. Activity of daptomycin against Gram-positive bacterial isolates from Indian medical centres (2006–2007)

    Article • International Journal of Antimicrobial Agents, November 2009, Elsevier

    Mr Douglas J Biedenbach

  32. Resurgence of Pseudomonas Endocarditis in Detroit, 2006-2008

    Article • Medicine, September 2009, Wolters Kluwer Health

    Mr Douglas J Biedenbach

  33. Multicenter evaluation of the in vitro activity of dalbavancin tested against staphylococci and streptococci in 5 European countries: results from the DECIDE Surveillance Program (2007)

    Article • Diagnostic Microbiology and Infectious Disease, June 2009, Elsevier

    Mr Douglas J Biedenbach

  34. Update of cefditoren activity tested against community-acquired pathogens associated with infections of the respiratory tract and skin and skin structures, including recent pharmacodynamic considerations

    Article • Diagnostic Microbiology and Infectious Disease, June 2009, Elsevier

    Mr Douglas J Biedenbach

  35. In vitro activity of iclaprim and comparison agents tested against Neisseria gonorrhoeae including medium growth supplement effects

    Article • Diagnostic Microbiology and Infectious Disease, March 2009, Elsevier

    Mr Douglas J Biedenbach

  36. Activities of Dalbavancin against a Worldwide Collection of 81,673 Gram-Positive Bacterial Isolates

    Article • Antimicrobial Agents and Chemotherapy, January 2009, ASM Journals

    Mr Douglas J Biedenbach

  37. Antimicrobial Activity of Prulifloxacin Tested against a Worldwide Collection of Gastroenteritis-Producing Pathogens, Including Those Causing Traveler's Diarrhea

    Article • Antimicrobial Agents and Chemotherapy, December 2008, ASM Journals

    Mr Douglas J Biedenbach

  38. Comparative in Vitro Activity of Zabofloxacin (DW-224a) Tested Against Multidrug-Resistant Neisseria gonorrhoeae

    Article • International Journal of Infectious Diseases, December 2008, Elsevier

    Mr Douglas J Biedenbach

  39. Dalbavancin Tested Against Staphylococcus spp. and Streptococcus spp. Isolates collected from Five European Counties: Comprehensive DECIDE Program Results (2007)

    Article • International Journal of Infectious Diseases, December 2008, Elsevier

    Mr Douglas J Biedenbach

  40. Dalbavancin Activity Tested Against a Contemporary Collection of Gram-positive Bacteria from Hospitals in the UK and Ireland: Results from DECIDE Program

    Article • International Journal of Infectious Diseases, December 2008, Elsevier

    Mr Douglas J Biedenbach

  41. Dalbavancin and Selected Comparison Agents Tested Against Indicated Gram-positive Isolates in European Medical Centers (Italy): Results from the DECIDE Program

    Article • International Journal of Infectious Diseases, December 2008, Elsevier

    Mr Douglas J Biedenbach

  42. Dalbavancin Comparative Activity Tested Against Gram-positive Species in German Medical Centers: Results from the DECIDE Program

    Article • International Journal of Infectious Diseases, December 2008, Elsevier

    Mr Douglas J Biedenbach

  43. Zabofloxacin (DW-224a) activity against Neisseria gonorrhoeae including quinolone-resistant strains

    Article • Diagnostic Microbiology and Infectious Disease, September 2008, Elsevier

    Mr Douglas J Biedenbach

  44. Antimicrobial activity of cefditoren tested against contemporary (2004–2006) isolates of Haemophilus influenzae and Moraxella catarrhalis responsible for community-acquired respiratory tract infections in the United States

    Article • Diagnostic Microbiology and Infectious Disease, June 2008, Elsevier

    Mr Douglas J Biedenbach

  45. Update of the Activity of Cefditoren and Comparator Oral β-lactam Agents Tested Against Community-AcquiredStreptococcus pneumoniaeIsolates (USA, 2004-2006)

    Article • Journal of Chemotherapy, April 2008, Taylor & Francis

    Mr Douglas J Biedenbach

  46. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia–Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003–2004)

    Article • International Journal of Antimicrobial Agents, August 2007, Elsevier

    Mr Douglas J Biedenbach

  47. P1805 Susceptibility analysis of gastroenteritis and beta–haemolytic streptococcal pathogens collected during a decade of SENTRY Antimicrobial Surveillance Program Monitoring in Europe (1997–2006)

    Article • International Journal of Antimicrobial Agents, March 2007, Elsevier

    Mr Douglas J Biedenbach

  48. P759 High-level multidrug-resistance among viridians group streptococci isolated from Turkey: report from the SENTRY Antimicrobial Surveillance Program

    Article • International Journal of Antimicrobial Agents, March 2007, Elsevier

    Mr Douglas J Biedenbach

  49. P1807 Resistance rates among selected Gram–positive and –negative isolates from European medical centres: a decade of SENTRY Program Surveillance (1997–2006)

    Article • International Journal of Antimicrobial Agents, March 2007, Elsevier

    Mr Douglas J Biedenbach

  50. Activity of Dalbavancin Tested against Staphylococcus spp. and  -Hemolytic Streptococcus spp. Isolated from 52 Geographically Diverse Medical Centers in the United States

    Article • Journal of Clinical Microbiology, January 2007, ASM Journals

    Mr Douglas J Biedenbach

  51. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: Report from the SENTRY Antimicrobial Surveillance Program (1998–2004)

    Article • Diagnostic Microbiology and Infectious Disease, January 2007, Elsevier

    Mr Douglas J Biedenbach

  52. Assessment of pathogen frequency and resistance patterns among pediatric patient isolates: Report from the 2004 SENTRY Antimicrobial Surveillance Program on 3 continents

    Article • Diagnostic Microbiology and Infectious Disease, December 2006, Elsevier

    Mr Douglas J Biedenbach

  53. Delayed resistance selection for doripenem when passaging Pseudomonas aeruginosa isolates with doripenem plus an aminoglycoside

    Article • Diagnostic Microbiology and Infectious Disease, July 2006, Elsevier

    Mr Douglas J Biedenbach

  54. Characterization of fluoroquinolone-resistant β-hemolytic Streptococcus spp. isolated in North America and Europe including the first report of fluoroquinolone-resistant Streptococcus dysgalactiae subspecies equisimilis: Report from the SENTRY Antimicr...

    Article • Diagnostic Microbiology and Infectious Disease, June 2006, Elsevier

    Mr Douglas J Biedenbach

  55. Microbiologic characterization of isolates from a dalbavancin clinical trial for catheter-related bloodstream infections

    Article • Diagnostic Microbiology and Infectious Disease, February 2006, Elsevier

    Mr Douglas J Biedenbach

  56. Susceptibility to amoxycillin–clavulanate among clinical isolates of Escherichia coli resistant to cefoxitin

    Article • Clinical Microbiology and Infection, February 2006, Elsevier

    Mr Douglas J Biedenbach

  57. Analysis of Salmonella spp. with resistance to extended-spectrum cephalosporins and fluoroquinolones isolated in North America and Latin America: report from the SENTRY Antimicrobial Surveillance Program (1997–2004)

    Article • Diagnostic Microbiology and Infectious Disease, January 2006, Elsevier

    Mr Douglas J Biedenbach

  58. Contemporary antimicrobial activity of triple antibiotic ointment: a multiphased study of recent clinical isolates in the United States and Australia

    Article • Diagnostic Microbiology and Infectious Disease, January 2006, Elsevier

    Mr Douglas J Biedenbach

  59. Emerging epidemic of metallo-β-lactamase–mediated resistances

    Article • Diagnostic Microbiology and Infectious Disease, February 2005, Elsevier

    Mr Douglas J Biedenbach

  60. Evolution and dissemination of extended-spectrum β-lactamase-producing Klebsiella pneumoniae: Epidemiology and molecular report from the SENTRY Antimicrobial Surveillance Program (1997–2003)

    Article • Diagnostic Microbiology and Infectious Disease, January 2005, Elsevier

    Mr Douglas J Biedenbach

  61. Cefdinir activity against contemporary North American isolates from community-acquired urinary tract infections

    Article • International Journal of Antimicrobial Agents, January 2005, Elsevier

    Mr Douglas J Biedenbach

  62. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997–2002)

    Article • Diagnostic Microbiology and Infectious Disease, September 2004, Elsevier

    Mr Douglas J Biedenbach

  63. Activities of Doripenem (S-4661) against Drug-Resistant Clinical Pathogens

    Article • Antimicrobial Agents and Chemotherapy, August 2004, ASM Journals

    Mr Douglas J Biedenbach

  64. Revision of linezolid disk diffusion quality control guidelines for testing Staphylococcus aureus ATCC 25923: an independent seven-laboratory trial

    Article • Clinical Microbiology and Infection, October 2003, Elsevier

    Mr Douglas J Biedenbach

  65. Global patterns of susceptibility for 21 commonly utilized antimicrobial agents tested against 48,440 Enterobacteriaceae in the SENTRY Antimicrobial Surveillance Program (1997-2001)

    Article • Diagnostic Microbiology and Infectious Disease, September 2003, Elsevier

    Mr Douglas J Biedenbach

  66. Susceptibility trends of haemophilus influenzae and Moraxella catarrhalis against orally administered antimicrobial agents: five-year report from the SENTRY Antimicrobial Surveillance Program

    Article • Diagnostic Microbiology and Infectious Disease, September 2003, Elsevier

    Mr Douglas J Biedenbach

  67. Antimicrobial susceptibility profile among β-haemolytic Streptococcus spp. collected in the SENTRY antimicrobial surveillance program—North America, 2001

    Article • Diagnostic Microbiology and Infectious Disease, August 2003, Elsevier

    Mr Douglas J Biedenbach

  68. Comparison of Streptococcus pneumoniae and Haemophilus influenzae susceptibilities from community-acquired respiratory tract infections and hospitalized patients with pneumonia: five-year results for the SENTRY antimicrobial surveillance program

    Article • Diagnostic Microbiology and Infectious Disease, August 2003, Elsevier

    Mr Douglas J Biedenbach

  69. Quality control guidelines for MIC susceptibility testing of NVP PDF-713: a novel peptide deformylase inhibitor

    Article • International Journal of Antimicrobial Agents, July 2003, Elsevier

    Mr Douglas J Biedenbach

  70. Initial Quality Control Evaluations for Susceptibility Testing of Dalbavancin (BI397), an Investigational Glycopeptide with Potent Gram-Positive Activity

    Article • Journal of Clinical Microbiology, June 2003, ASM Journals

    Mr Douglas J Biedenbach

  71. Validation of commercial dry-form broth microdilution panels for susceptibility testing of AZD2563, a new long-acting oxazolidinone

    Article • Clinical Microbiology and Infection, June 2003, Elsevier

    Mr Douglas J Biedenbach

  72. Re-evaluation of quality control guidelines for gatifloxacin and garenoxacin (BMS284756) when susceptibility testing Haemophilus influenzae and Streptococcus pneumoniae

    Article • Diagnostic Microbiology and Infectious Disease, June 2003, Elsevier

    Mr Douglas J Biedenbach

  73. Geographic variations and trends in antimicrobial resistance among Enterococcus faecalis and Enterococcus faecium in the SENTRY Antimicrobial Surveillance Program (1997–2000)

    Article • Diagnostic Microbiology and Infectious Disease, May 2003, Elsevier

    Mr Douglas J Biedenbach

  74. Five-year analysis of Haemophilus influenzae isolates with reduced susceptibility to fluoroquinolones: prevalence results from the SENTRY antimicrobial surveillance program

    Article • Diagnostic Microbiology and Infectious Disease, May 2003, Elsevier

    Mr Douglas J Biedenbach

  75. Influence of patient age on the susceptibility patterns of Streptococcus pneumoniae isolates in North America (2000-2001): report from the SENTRY Antimicrobial Surveillance Program

    Article • Diagnostic Microbiology and Infectious Disease, May 2003, Elsevier

    Mr Douglas J Biedenbach

  76. Comparative activity of garenoxacin (BMS 284756), a novel desfluoroquinolone, tested against 8,331 isolates from community-acquired respiratory tract infections: North American results from the SENTRY Antimicrobial Surveillance Program (1999–2001)

    Article • Diagnostic Microbiology and Infectious Disease, April 2003, Elsevier

    Mr Douglas J Biedenbach

  77. Pathogen of occurrence and susceptibility patterns associated with pneumonia in hospitalized patients in North America: results of the SENTRY Antimicrobial Surveillance Study (2000)

    Article • Diagnostic Microbiology and Infectious Disease, April 2003, Elsevier

    Mr Douglas J Biedenbach

  78. Sustained activity and spectrum of selected extended-spectrum β-lactams (carbapenems and cefepime) against Enterobacter spp. and ESBL-producing Klebsiella spp.: report from the SENTRY antimicrobial surveillance program (USA, 1997–2000)

    Article • International Journal of Antimicrobial Agents, January 2003, Elsevier

    Mr Douglas J Biedenbach

  79. Molecular Epidemiology of Extended-Spectrum  -Lactamase-Producing, Fluoroquinolone-Resistant Isolates of Klebsiella pneumoniae in Taiwan

    Article • Journal of Clinical Microbiology, December 2002, ASM Journals

    Mr Douglas J Biedenbach

  80. Evaluation of the in vitro activity of six broad-spectrum β-lactam antimicrobial agents tested against recent clinical isolates from India: a survey of ten medical center laboratories

    Article • Diagnostic Microbiology and Infectious Disease, December 2002, Elsevier

    Mr Douglas J Biedenbach

  81. Multicentre assessment of linezolid antimicrobial activity and spectrum in Europe: report from the Zyvox® antimicrobial potency study (ZAPS-Europe)

    Article • Clinical Microbiology and Infection, December 2002, Elsevier

    Mr Douglas J Biedenbach

  82. Four-year evaluation of frequency of occurrence and antimicrobial susceptibility patterns of bacteria from bloodstream infections in Latin American medical centers

    Article • Diagnostic Microbiology and Infectious Disease, November 2002, Elsevier

    Mr Douglas J Biedenbach

  83. In Vitro Evaluation of AZD2563, a Novel Oxazolidinone, against 603 Recent Staphylococcal Isolates

    Article • Antimicrobial Agents and Chemotherapy, August 2002, ASM Journals

    Mr Douglas J Biedenbach

  84. Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (2000)

    Article • Diagnostic Microbiology and Infectious Disease, August 2002, Elsevier

    Mr Douglas J Biedenbach

  85. Evaluation of in vitro susceptibility testing criteria for gemifloxacin when tested against Haemophilus influenzae strains with reduced susceptibility to ciprofloxacin and ofloxacin

    Article • Diagnostic Microbiology and Infectious Disease, August 2002, Elsevier

    Mr Douglas J Biedenbach

  86. Pathogen occurrence and antimicrobial resistance trends among urinary tract infection isolates in the Asia-Western Pacific Region: report from the SENTRY Antimicrobial Surveillance Program, 1998–1999

    Article • International Journal of Antimicrobial Agents, July 2002, Elsevier

    Mr Douglas J Biedenbach

  87. Geographic variations in activity of broad-spectrum β-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997–2000)

    Article • Diagnostic Microbiology and Infectious Disease, July 2002, Elsevier

    Mr Douglas J Biedenbach

  88. Antimicrobial susceptibility patterns of β-hemolytic and viridans group streptococci: report from the SENTRY Antimicrobial Surveillance Program (1997–2000)

    Article • Diagnostic Microbiology and Infectious Disease, June 2002, Elsevier

    Mr Douglas J Biedenbach

  89. Multicenter assessment of the linezolid spectrum and activity using the disk diffusion and Etest methods: report of the Zyvox® Antimicrobial Potency Study in Latin America (LA-ZAPS)

    Article • The Brazilian Journal of Infectious Diseases, June 2002, FapUNIFESP (SciELO)

    Mr Douglas J Biedenbach

  90. Comparative antimicrobial spectrum and activity of the desfluoroquinolone BMS284756 (T-3811) tested against non-fermentative Gram-negative bacilli

    Article • Clinical Microbiology and Infection, June 2002, Elsevier

    Mr Douglas J Biedenbach

  91. A multicenter evaluation of linezolid antimicrobial activity in North America

    Article • Diagnostic Microbiology and Infectious Disease, May 2002, Elsevier

    Mr Douglas J Biedenbach

  92. Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998–2000

    Article • Diagnostic Microbiology and Infectious Disease, May 2002, Elsevier

    Mr Douglas J Biedenbach

  93. Potency and antimicrobial spectrum update for piperacillin/tazobactam (2000): emphasis on its activity against resistant organism populations and generally untested species causing community-acquired respiratory tract infections

    Article • Diagnostic Microbiology and Infectious Disease, May 2002, Elsevier

    Mr Douglas J Biedenbach

  94. In vitro evaluation of AZD2563, a new oxazolidinone, tested against unusual gram-positive species

    Article • Diagnostic Microbiology and Infectious Disease, February 2002, Elsevier

    Mr Douglas J Biedenbach

  95. Linezolid-resistant Enterococcus faecium isolated from a patient without prior exposure to an oxazolidinone: report from the SENTRY Antimicrobial Surveillance Program

    Article • Diagnostic Microbiology and Infectious Disease, February 2002, Elsevier

    Mr Douglas J Biedenbach

  96. Antimicrobial Susceptibility Testing of Clinical Isolates of Bordetella pertussis from Northern California: Report from the SENTRY Antimicrobial Surveillance Program

    Article • Antimicrobial Agents and Chemotherapy, December 2001, ASM Journals

    Mr Douglas J Biedenbach

  97. Antimicrobial resistance trends in medical centers using carbapenems: report of 1999 and 2000 results from the MYSTIC program (USA)

    Article • Diagnostic Microbiology and Infectious Disease, December 2001, Elsevier

    Mr Douglas J Biedenbach

  98. Assessment of BMS284756 MIC and 5-μg disk diffusion quality control studies tested against seven American type culture collection strains

    Article • Diagnostic Microbiology and Infectious Disease, December 2001, Elsevier

    Mr Douglas J Biedenbach

  99. Antimicrobial activity of BMS 284756 (T-3811) against Neisseria gonorrhoeae tested by three methods

    Article • International Journal of Antimicrobial Agents, November 2001, Elsevier

    Mr Douglas J Biedenbach

  100. In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum β-lactamases

    Article • Diagnostic Microbiology and Infectious Disease, August 2001, Elsevier

    Mr Douglas J Biedenbach

  101. Comparative antimicrobial spectrum and activity of BMS284756 (T-3811, a desfluoroquinolone) tested against 656 Enterobacteriaceae, including preliminary in vitro susceptibility test comparisons and development

    Article • International Journal of Antimicrobial Agents, August 2001, Elsevier

    Mr Douglas J Biedenbach

  102. Comparative antimicrobial activity of ABT-773, a novel ketolide, tested against drug-resistant Gram-positive cocci and Haemophilus influenzae

    Article • International Journal of Antimicrobial Agents, June 2001, Elsevier

    Mr Douglas J Biedenbach

  103. Validation of cefditoren MIC quality control ranges by a multi-laboratory study (2001)

    Article • Diagnostic Microbiology and Infectious Disease, April 2001, Elsevier

    Mr Douglas J Biedenbach

  104. Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States

    Article • Diagnostic Microbiology and Infectious Disease, April 2001, Elsevier

    Mr Douglas J Biedenbach

  105. Activity of BMS284756 (T-3811) tested against anaerobic bacteria, Campylobacter jejuni, Helicobacter pylori and Legionella spp.

    Article • Diagnostic Microbiology and Infectious Disease, April 2001, Elsevier

    Mr Douglas J Biedenbach

  106. Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby-Bauer disk diffusion method: Report of the Zyvox® Antimicrobial Potency Study (ZAPS) in the United States

    Article • Diagnostic Microbiology and Infectious Disease, April 2001, Elsevier

    Mr Douglas J Biedenbach

  107. Antimicrobial susceptibility of quinupristin/dalfopristin tested against gram-positive cocci from Latin America: results from the Global SMART (GSMART) surveillance study

    Article • The Brazilian Journal of Infectious Diseases, February 2001, FapUNIFESP (SciELO)

    Mr Douglas J Biedenbach

  108. Carbapenem-resistant Serratia marcescens isolates producing Bush group 2f β-lactamase (SME-1) in the United States: results from the MYSTIC Programme

    Article • Diagnostic Microbiology and Infectious Disease, February 2001, Elsevier

    Mr Douglas J Biedenbach

  109. In vitro activity of linezolid (U-100766) against Haemophilus influenzae measured by three different susceptibility testing methods

    Article • Diagnostic Microbiology and Infectious Disease, January 2001, Elsevier

    Mr Douglas J Biedenbach

  110. In VitroEvaluation of BI 397, a Novel Glycopeptide Antimicrobial Agent

    Article • Journal of Chemotherapy, January 2001, Taylor & Francis

    Mr Douglas J Biedenbach

  111. Antimicrobial activity and in vitro susceptibility test development for cefditoren against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus species

    Article • Diagnostic Microbiology and Infectious Disease, June 2000, Elsevier

    Mr Douglas J Biedenbach

  112. Cefditoren activity against nearly 1000 non-fastidious bacterial isolates and the development of in vitro susceptibility test methods

    Article • Diagnostic Microbiology and Infectious Disease, June 2000, Elsevier

    Mr Douglas J Biedenbach

  113. Fluoroquinolone-resistant Haemophilus influenzae: Frequency of occurrence and analysis of confirmed strains in the SENTRY antimicrobial surveillance program (North and Latin America)

    Article • Diagnostic Microbiology and Infectious Disease, April 2000, Elsevier

    Mr Douglas J Biedenbach

  114. A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia☆

    Article • Diagnostic Microbiology and Infectious Disease, March 2000, Elsevier

    Mr Douglas J Biedenbach

  115. Pharyngeal colonization prevalence rates for Streptococcus pyogenes and Streptococcus pneumoniae in a respiratory chemoprophylaxis intervention study using azithromycin

    Article • Clinical Microbiology and Infection, January 2000, Elsevier

    Mr Douglas J Biedenbach, Professor Gregory C Gray

  116. In vitro evaluation of cefepime and other broad-spectrum β-lactams in Taiwan medical centers

    Article • Diagnostic Microbiology and Infectious Disease, December 1999, Elsevier

    Mr Douglas J Biedenbach

  117. In vitro evaluation of cefepime and other broad-spectrum β-lactams in 22 medical centers in Japan: a phase II trial comparing two annual organism samples

    Article • Diagnostic Microbiology and Infectious Disease, December 1999, Elsevier

    Mr Douglas J Biedenbach

  118. In vitro evaluation of cefepime and other broad-spectrum β-lactams for isolates in Malaysia and Singapore medical centers

    Article • Diagnostic Microbiology and Infectious Disease, December 1999, Elsevier

    Mr Douglas J Biedenbach

  119. In vitro evaluation of cefepime and other broad-spectrum β-lactams against bacteria from Indonesian medical centers

    Article • Diagnostic Microbiology and Infectious Disease, December 1999, Elsevier

    Mr Douglas J Biedenbach

  120. In vitro evaluation of cefepime and other broad-spectrum β-lactams in eight medical centers in Thailand

    Article • Diagnostic Microbiology and Infectious Disease, December 1999, Elsevier

    Mr Douglas J Biedenbach

  121. In vitro evaluation of broad-spectrum β-lactams in the Philippines medical centers: role of fourth-generation cephalosporins

    Article • Diagnostic Microbiology and Infectious Disease, December 1999, Elsevier

    Mr Douglas J Biedenbach

  122. In vitro evaluation of broad-spectrum β-lactams tested in medical centers in Korea: role of fourth-generation cephalosporins

    Article • Diagnostic Microbiology and Infectious Disease, December 1999, Elsevier

    Mr Douglas J Biedenbach

  123. Development of in vitro susceptibility testing methods for gemifloxacin (formerly LB20304a or SB-265805), an investigational fluoronaphthyridone

    Article • Diagnostic Microbiology and Infectious Disease, November 1999, Elsevier

    Mr Douglas J Biedenbach

  124. Evaluation of the in vitro antimicrobial activity of cefepime compared to other broad-spectrum β-lactams tested against recent clinical isolates from 10 Chinese hospitals

    Article • Diagnostic Microbiology and Infectious Disease, October 1999, Elsevier

    Mr Douglas J Biedenbach

  125. Comparative In Vitro Activity of Gatifloxacin Against Stenotrophomonas maltophilia and Burkholderia Species Isolates Including Evaluation of Disk Diffusion and E Test Methods

    Article • European Journal of Clinical Microbiology & Infectious Diseases, July 1999, Springer Science + Business Media

    Mr Douglas J Biedenbach

  126. Phenotypic and genotypic characterizations of chinese strains of Escherichia coli producing extended-spectrum β-lactamases

    Article • Diagnostic Microbiology and Infectious Disease, July 1999, Elsevier

    Mr Douglas J Biedenbach

  127. Comparative antimicrobial activity of gatifloxacin tested against Streptococcus spp. including quality control guidelines and etest method validation

    Article • Diagnostic Microbiology and Infectious Disease, June 1999, Elsevier

    Mr Douglas J Biedenbach

  128. Evaluation of the in vitro activity of six broad-spectrum β-lactam antimicrobial agents tested against over 2,000 clinical isolates from 22 medical centers in Japan

    Article • Diagnostic Microbiology and Infectious Disease, June 1999, Elsevier

    Mr Douglas J Biedenbach

  129. Determination of the antimicrobial activity of 29 clinically important compounds tested against fastidious HACEK group organisms

    Article • Diagnostic Microbiology and Infectious Disease, May 1999, Elsevier

    Mr Douglas J Biedenbach

  130. Gatifloxacin (AM-1155, CG 5501) susceptibility testing interpretive criteria and quality control guidelines for dilution and disk (5-μg) diffusion methods

    Article • Diagnostic Microbiology and Infectious Disease, April 1999, Elsevier

    Mr Douglas J Biedenbach

  131. Comparative in vitro evaluation of dirithromycin tested against recent clinical isolates of Haemophilus influenzae, moraxella catarrhalis, and streptococcus pneumoniae, including effects of medium supplements and test conditions on MIC results

    Article • Diagnostic Microbiology and Infectious Disease, April 1999, Elsevier

    Mr Douglas J Biedenbach

  132. Antistreptococcal Activity of Gatifloxacin

    Article • Drugs, January 1999, Springer Science + Business Media

    Mr Douglas J Biedenbach

  133. Antimicrobial Activity of Gatifloxacin Against Stenotrophomonas maltophilia and Burkholderia spp.

    Article • Drugs, January 1999, Springer Science + Business Media

    Mr Douglas J Biedenbach

  134. Gatifloxacin Susceptibility Testing Interpretive Criteria and Quality Control Guidelines for Dilution and Disk Diffusion Methods

    Article • Drugs, January 1999, Springer Science + Business Media

    Mr Douglas J Biedenbach

  135. In Vitro Antimicrobial Activity of Gatifloxacin Against N. gonorrhoeaeand H. influenzae

    Article • Drugs, January 1999, Springer Science + Business Media

    Mr Douglas J Biedenbach

  136. Antimicrobial activity of gatifloxacin tested against Neisseria gonorrhoeae using three methods and a collection of fluoroquinolone-resistant strains

    Article • Diagnostic Microbiology and Infectious Disease, December 1998, Elsevier

    Mr Douglas J Biedenbach

  137. Evaluation of the Vitek System to accurately test the susceptibility of Pseudomonas aeruginosa clinical isolates against cefepime

    Article • Diagnostic Microbiology and Infectious Disease, October 1998, Elsevier

    Mr Douglas J Biedenbach

  138. In vitro evaluation of a novel orally administered cephalosporin (cefditoren) tested against 1249 recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae

    Article • Diagnostic Microbiology and Infectious Disease, August 1998, Elsevier

    Mr Douglas J Biedenbach

  139. Antimicrobial Activity of Quinupristin-Dalfopristin (RP 59500, Synercid®) Tested against Over 28,000 Recent Clinical Isolates from 200 Medical Centers in the United States and Canada

    Article • Diagnostic Microbiology and Infectious Disease, July 1998, Elsevier

    Mr Douglas J Biedenbach

  140. Comparative Antimicrobial Activity and Kill-Curve Investigations of Novel Ketolide Antimicrobial Agents (HMR 3004 and HMR 3647) Tested against Haemophilus influenzae and Moraxella catarrhalis Strains

    Article • Diagnostic Microbiology and Infectious Disease, June 1998, Elsevier

    Mr Douglas J Biedenbach

  141. Anti-Legionella activity of trovafloxacin compared with seven other antimicrobial agents including an intermethod evaluation

    Article • Diagnostic Microbiology and Infectious Disease, September 1997, Elsevier

    Mr Douglas J Biedenbach

  142. Antimicrobial activity of RU-66647, a new ketolide

    Article • Diagnostic Microbiology and Infectious Disease, January 1997, Elsevier

    Mr Douglas J Biedenbach

  143. Validation of Etest for seven antimicrobial agents using regulatory criteria for the assessment of antimicrobial susceptibility devices

    Article • Diagnostic Microbiology and Infectious Disease, January 1997, Elsevier

    Mr Douglas J Biedenbach

  144. The comparative antimicrobial activity of levofloxacin tested against 350 clinical isolates of streptococci

    Article • Diagnostic Microbiology and Infectious Disease, May 1996, Elsevier

    Mr Douglas J Biedenbach

  145. Reevaluation of contemporary laboratory methods for detection of antimicrobial resistance among enterococci

    Article • Clinical Microbiology and Infection, March 1996, Elsevier

    Mr Douglas J Biedenbach

  146. Comparative in-vitro activity of quinupristin/ dalfopristin (RP 59500) tested against penlcillin-and macrolide-resistant pneumococci by the Etest

    Article • Journal of Antimicrobial Chemotherapy, January 1996, Oxford University Press (OUP)

    Mr Douglas J Biedenbach

  147. Activity of two novel fluoroquinolones (DU-6859a and DV-7751a) tested against glycopeptide-resistant enterococcal isolates

    Article • Diagnostic Microbiology and Infectious Disease, November 1995, Elsevier

    Mr Douglas J Biedenbach

  148. Antimicrobial activity of CS-940, a new trifluorinated quinolone

    Article • Antimicrobial Agents and Chemotherapy, October 1995, ASM Journals

    Mr Douglas J Biedenbach

  149. Evalution of Vitek and API 20S for species identification of enterococci

    Article • Diagnostic Microbiology and Infectious Disease, August 1995, Elsevier

    Mr Douglas J Biedenbach

  150. In vitro evaluation of DV-7751a, a new fluoroquinolone with an enhanced spectrum of activity against gram-positive aerobic organisms and anaerobes

    Article • Antimicrobial Agents and Chemotherapy, July 1995, ASM Journals

    Mr Douglas J Biedenbach

  151. Interpretive errors using an automated system for the susceptibility testing of imipenem and aztreonam

    Article • Diagnostic Microbiology and Infectious Disease, January 1995, Elsevier

    Mr Douglas J Biedenbach

  152. Development, characterization, and initial evaluations of S1 a new chromogenic cephalosporin for β-lactamase delection

    Article • Diagnostic Microbiology and Infectious Disease, January 1995, Elsevier

    Mr Douglas J Biedenbach

  153. Interpretive criteria for susceptibility tests with DU-6859a and FK-037 tested against Haemophilus influenzae and Neisseria gonorrhoeae

    Article • Diagnostic Microbiology and Infectious Disease, June 1994, Elsevier

    Mr Douglas J Biedenbach